Objective: Alvimopan use has reduced the length of hospital stay in patients undergoing major abdominal surgeries and radical cystectomy. Retroperitoneal lymph node dissection for testicular cancer may be associated with delayed gastrointestinal recovery prolonging hospital length of stay. We evaluate whether alvimopan is associated with enhanced gastrointestinal recovery and shorter hospital length of stay in men undergoing retroperitoneal lymph node dissection for testicular cancer. Materials and methods: From 2010 to 2016, 29 patients underwent open, transperitoneal bilateral template retroperitoneal lymph node dissection. Data for patients who received alvimopan were prospectively collected and compared to a historical cohort of patients who did not receive alvimopan. Primary outcome measures were length of stay and recovery of gastrointestinal function. Descriptive statistics were reported. Time-to-event outcomes were evaluated using cumulative incidence curves and log rank test. Factors associated with length of stay were analyzed for correlation using multiple linear regression. Results: Of 29 men undergoing retroperitoneal lymph node dissection, eight received alvimopan and 21 did not. The two cohorts were well matched, with no significant differences. In the alvimopan cohort compared with those who did not receive alvimopan median time to return of flatus was 2 versus 4 days (p=0.0002), and median time to first bowel movement was 2.5 versus 5 days (p=0.046), respectively. Median length of stay in the alvimopan cohort was 4 days versus 6 days in those who did not receive alvimopan (p=0.074). In adjusted analyses, receipt of alvimopan did not influence length of stay. Conclusion: Alvimopan may facilitate gastrointestinal recovery after retroperitoneal lymph node dissection for testicular cancer. Whether this translates into reduced length of stay needs to be determined by randomized controlled trials using larger cohorts. Level of evidence: 3b.
Introduction
Testicular cancer or germ cell tumor (GCT) is the most common solid tumor in men between the ages of 20 and 34 years. 1 With current multidisciplinary approaches to treatment, long-term survival rates, even for men with metastatic GCT, exceed 90%. This is largely due to the development of cisplatin-based chemotherapy, reliable tumor markers available for this disease, and the appropriate integration of and refinements in surgery over time. [2] [3] [4] Given the high cure rates in these men, treatment objectives should focus on minimizing treatment-related toxicities.
Retroperitoneal lymph node dissection (RPLND) is a well-established therapy to treat GCTs in the primary or post-chemotherapy setting. RPLND can be technically challenging, with overall complication rates for primary RPLND and post-chemotherapy RPLND reported to be 10-24% 5-8 and 20-30%, 9, 10 respectively. Postoperative paralytic ileus, which can delay immediate recovery, increase postoperative morbidity, extend a patient's hospital length of stay (LOS), and increase costs, 11, 12 has been reported in up to 18% of men undergoing primary RPLND and up to 21% of men undergoing post-chemotherapy RPLND. 7 To facilitate quicker return of bowel function and shorten LOS, researchers have reported on an extraperitoneal approach to RPLND. 13 Alvimopan (trade name Entereg; Merck) is an oral medication that works as a µ-opioid receptor antagonist to reduce the incidence and severity of postoperative ileus in post-surgical patients. Randomized controlled trials in the general surgical and urological literature have demonstrated the benefit of alvimopan in reducing LOS and decreasing the incidence of postoperative ileus. 14, 15 In the urological field, alvimopan has been studied in patients undergoing radical cystectomy with urinary diversion for invasive bladder cancer. 16 In fact, enhanced recovery after surgery (ERAS) protocols, which are evidence-based pathways that aim to optimize and standardize the perioperative care of patients receiving complex surgeries, have adopted alvimopan as a standard part of the ERAS protocol, to shorten LOS without compromising post-surgery outcomes. 17 To our knowledge, alvimopan has yet to be investigated in the testicular cancer population after surgery. In this study, we evaluate whether alvimopan is associated with enhanced gastrointestinal recovery and shorter hospital LOS in men undergoing RPLND for testicular cancer.
Materials and methods

Study population
Men who received a RPLND for testicular cancer from March 2010 to August 2016 at our center were included in this study. All patients underwent an open, transperitoneal bilateral-template RPLND (nerve sparing when feasible) by a single surgeon. Patients who, for whatever reason, received prescription opioid narcotic medications prior to RPLND were excluded from the study. The study was reviewed and approved by the institutional review board at the Rutgers Cancer Institute of New Jersey.
Description of the intervention
Patients received a single dose of alvimopan 12 mg tablet orally 30 minutes preoperatively and then alvimopan was readministered every 12 hours postoperatively for up to 14 doses and discontinued only on discharge or if the patient received the maximum 15 doses. 18 
Post-surgical care
All patients received general anesthesia. Post-surgery pain management was provided by intravenous hydromorphone patient controlled analgesia until advanced to and tolerating a clear liquid diet, after which they were placed on either oral hydromorphone or acetaminophen/oxycodone.
Diet and activity were advanced as tolerated. On the first postoperative day, patients were started on sips of clear liquids if it was tolerated and the diet was sequentially advanced during hospitalization to clear liquid diet and then regular diet when tolerated. Patients were considered to be tolerating the diet if they did not experience nausea, vomiting, or abdominal distension.
Patients were seen twice daily by the operative team, between 6 a.m. and 8 a.m. and between 5 p.m. and 7 p.m. and questioned during each visit whether the passage of flatus and/or first bowel movement has occurred.
Patients were deemed appropriate for discharge when no complications were present, they were tolerating oral nutrition, pain was controlled on oral analgesics, and gastrointestinal function had returned (flatus or bowel movement).
Study endpoints
Two comparative arms, those who received alvimopan during their RPLND hospitalization and those who did not, were assessed. Data for men who received alvimopan were prospectively collected and compared to a historical cohort of patients who did not receive alvimopan. Primary outcomes measured were length of hospital stay and recovery of gastrointestinal function, which we defined as time to return of flatus and time to first bowel movement.
Statistical analysis
Descriptive statistics were calculated for patient clinical and demographic characteristics, according to whether patients received alvimopan or not. Univariate comparison for each variable was performed using chi-square tests for categorical variables and Mann-Whitney-Wilcoxon tests for continuous variables. For each of the time to event outcomes, namely time to return of flatus and time to first bowel movement after surgery, cumulative incidence curves were plotted. The log rank test was used to determine the significance of treatment effects between the two arms. Potential factors associated with hospital LOS were analyzed for correlation using a multiple linear regression approach. Both unadjusted and adjusted regression analyses were performed. Time-to-event analyses and multiple linear regression were conducted using R statistical software version 3.4.2 (https://www.r-project.org/). Statistical tests were determined to be significant at a two-sided p-value of less than 0.05.
Results
From March 2010 to August 2016, 29 patients who underwent RPLND by a single surgeon met the inclusion criteria. Of those patients, 23 (79.3%) received RPLND in the post-chemotherapy setting while six (20.7%) received RPLND in the primary setting. When comparing the cohort of patients who received alvimopan to those who did not, there were no significant differences between the two groups with respect to age, proportion with non-seminomatous GCT histology, proportion who received postchemotherapy RPLND, preoperative mass size, body mass index, smoking history, comorbidity index score, estimated blood loss, or the need for transfusion (Table 1 ).
In total, six patients (20.1%) had complications at 90 days, of which one (3.4%) was Clavien grade 1 (nausea requiring anti-emetics) and two (6.8%) were Clavien grade 2 (one patient developed a pulmonary embolus requiring anticoagulation, another developed Clostridium difficile infection requiring antimicrobial treatment). There were two Clavien grade 3a complications (6.8%), one of which was a symptomatic lymphocele requiring image-guided drainage and another developed biliary obstruction secondary to pre-existing choledocholithiasis (unrelated to RPLND) requiring endoscopic retrograde cholangiopancreatography. Finally, one patient (3.4%) experienced a Clavien grade 4 complication, namely post-surgery acute respiratory distress syndrome from bleomycin-induced pneumonitis requiring intensive care monitoring and temporary ventilatory support. Table 2 reports Clavien-Dindo complications at 90 days, according to whether alvimopan was received or not.
Alvimopan use did appear to enhance gastrointestinal recovery, decreasing both the median time to flatus and the median time to first bowel movement after surgery. More specifically, the median time to the return of flatus in men receiving alvimopan was 2 days compared to 4 days for those who did not (log rank test p-value 0.0002) (Figure 1(a) ). The median time to first bowel movement in men receiving alvimopan was 2.5 days versus 5 days for those who did not (log rank test p-value 0.046) (Figure 1(b) ).
Median hospital LOS for men receiving alvimopan compared with those men who did not was 4 days versus 6 days, respectively (p=0.074). To explore the association of several factors that may increase LOS after RPLND, we analyzed, using a multiple linear regression approach, whether receipt of alvimopan (vs. no receipt), RPLND approach (primary vs. post-chemotherapy) and Clavien grade complications, were associated with LOS. Both unadjusted and adjusted regression analyses demonstrate that LOS is influenced mainly by Clavien grade complications, and was not associated with alvimopan use or with the setting in which RPLND was performed (primary vs. post-chemotherapy) ( Table 3 ). For example, on adjusted analyses, there was an incremental increase in hospital LOS (days) according to Clavien grade classification, with 
Discussion
Major abdominal surgeries increase the risk of postoperative paralytic ileus secondary to bowel manipulation, spinal-intestinal neural reflexes, secretion of inflammatory mediators, anesthetics, and postoperative opioid use. ERAS protocols are standardized, multi-modal perioperative care pathways developed to reduce morbidity after major abdominal surgery. Alvimopan has been incorporated into these ERAS protocols and has been shown to improve outcomes in the general surgical literature. 14, 19 This success has prompted investigations of its use in other types of surgeries, in particular urological procedures. Two randomized controlled trials demonstrated that alvimopan accelerates gastrointestinal recovery in patients who undergo radical cystectomy with urinary diversion. 16, 20 Lee et al. showed that alvimopan accelerated gastrointestinal recovery, defined as tolerating a diet and first bowel movement, compared to placebo, in patients undergoing radical cystectomy with urinary diversion. In their study, investigators showed that the alvimopan cohort experienced a quicker time to first bowel movement (5.5 days vs. 6.8 days, p<0.0001) and shorter mean LOS (7.4 vs. 10.1 days, p=0.0051). 16 Likewise, similar findings were demonstrated in a study by Kauf et al., which reported a mean LOS reduction of 2.63 days with the use of alvimopan (p=0.005). 20 Theoretically, alvimopan may accelerate gastrointestinal recovery and shorten LOS after RPLND, a urological surgery with reported ileus rates of up to 20%, as it requires exteriorization of bowel to expose the great vessels. 7 To our knowledge, the use of alvimopan to enhance post-surgical recovery after RPLND for men with testicular cancer has yet to be reported.
Our analysis aimed to determine whether alvimopan enhanced gastrointestinal recovery and shortened hospital LOS in this population. Several key findings were observed. First, alvimopan use did appear to facilitate gastrointestinal recovery, significantly decreasing both the median time to flatus and the median time to first bowel movement after surgery. Return of flatus and of bowel movements occurred 2 and 2.5 days earlier, respectively, in the cohort of men who received alvimopan when compared to those who did not. However, in our study cohort, enhanced gastrointestinal recovery did not translate into shorter LOS for men receiving alvimopan. Although there was a trend towards shorter median hospital LOS for the alvimopan cohort (4 days vs. 6 days, p=0.074), these results were not statistically significant, nor was alvimopan use, on unadjusted and adjusted analyses, associated with hospital LOS. To further determine the relative influence of co-dependent factors (i.e. alvimopan use, Clavien complications, setting of RPLND) that may influence LOS and assess each factor's relative influence, we performed a multiple linear regression analysis. On unadjusted and adjusted analysis, the major determinant influencing LOS was the presence of complications postoperatively. Not surprisingly, there was an incremental increase in hospital LOS (days) according to Clavien grade classification, with patients who had higher grade complications having extended LOSs. Receipt of alvimopan or whether patients received a RPLND in the primary or post-chemotherapy setting did not influence hospital LOS.
Our findings are analogous with the published literature demonstrating that alvimopan enhances gastrointestinal recovery after colorectal surgery and radical cystectomy. 14, 16, [20] [21] [22] [23] [24] [25] [26] However, we were not able to demonstrate a reduction in LOS with alvimopan use. This study has several limitations. First, our pilot study comprised a small sample size of men from a single institution. Second, although the alvimopan cohort was prospectively evaluated, the comparative arm included a historical cohort in which data collection was retrospective in nature. Despite this, our cohorts were well matched in terms of clinical and demographic characteristics, with no significant differences in the variables analyzed. Finally, hospital LOS is a complex endpoint to evaluate, as many factors, some co-dependent, in the pre, intra and postoperative setting, can influence its outcome. Although we found a trend towards shorter LOS in the alvimopan cohort (4 days vs. 6 days), the results were not statistically significant and when subjected to a multivariable regression analysis, alvimopan use did not appear to influence LOS in this population.
Our initial exploratory study, although limited by its small sample size, identifies a potentially promising modality to be incorporated into ERAS protocols to enhance gastrointestinal recovery in patients with testicular cancer undergoing RPLND. Randomized controlled trials with larger cohorts will be needed to validate the findings of enhanced gastrointestinal recovery in this population and to clarify whether the receipt of alvimopan can reduce LOS and hospitalization costs.
The use of alvimopan may facilitate gastrointestinal recovery in men undergoing RPLND for testicular cancer, reducing the time to flatus and reducing the time to first bowel movement after surgery. Whether this translates into reduced hospital LOS and decreased hospitalization costs needs to be determined by randomized controlled trials using larger cohorts.
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